title: Melanoma: Advances in Targeted Therapy and Molecular Markers.
abstract: OBJECTIVE
  In recent years, there have been dramatic improvements in the diagnosis and treatment of patients with melanoma. The development of molecular markers and associated targeted therapies have given new hope to subsets of patients with advanced disease. Here we discuss the most important advances in molecular targeted therapy and how these developments are likely to affect the practice of the clinical surgeon.
  
  
  CONCLUSIONS
  Germ-line and somatic mutations are common in melanoma and provide prognostic information that can now be harnessed to provide a more personalized approach to cancer treatment. BRAF mutation at the V600 position is the most commonly identified mutation in patients with melanoma. Treatment with targeted inhibitors in patients with BRAF-mutant melanoma has afforded dramatic responses in about half of selected patients. Unfortunately, disease control is not durable and recurrences are common. We predict an increasing role for the surgeon in the multidisciplinary treatment of patients with metastatic disease, as well as a role for molecular profiling in patients with high-risk early stage disease. Further, we are only beginning to understand the prognostic significance of various gene mutations in patients with melanoma.
authors.affiliation: Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Danielle K
authors.initials: DK
authors.lastname: DePeralta
authors.affiliation: Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. genevieveboland@gmail.com.
authors.forename: Genevieve M
authors.initials: GM
authors.lastname: Boland
mesh_terms: D018095:Germ-Line Mutation; D006801:Humans; D007167:Immunotherapy; D020935:MAP Kinase Signaling System / Q000235:genetics*; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics* / Q000601:surgery; D058990:Molecular Targeted Therapy; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics*
chemical_list: C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf